文献速递间质性肺疾病

托珠单抗治疗系统性硬化症:3期随机双盲安慰剂对照试验

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2020-08-28

这项多中心3期试验纳入210例病程≤60个月、改良Rodnan皮肤评分10-35的弥漫性皮肤型系统性硬化症成人,随机接受每周皮下托珠单抗162 mg或安慰剂48周。主要终点mRSS变化组间差异未达统计学意义;FVC%预测值变化分布及变化量 favour 托珠单抗,提示其可能保护早期SSc-ILD且急性期反应物升高者的肺功能,安全性与此前已知特征一致。

要点

  • 主要皮肤纤维化终点未达到,mRSS变化组间差异无统计学意义。
  • FVC%预测值变化倾向托珠单抗,提示可能保护早期SSc-ILD肺功能。
  • 感染为最常见不良事件,两组发生率相近,安全性与此前已知特征一致。

核心结论

  • 主要皮肤纤维化终点未达到。
  • FVC%预测值这一次要终点的结果提示托珠单抗可能保护早期SSc-ILD且急性期反应物升高者的肺功能。
  • 安全性与此前已知的托珠单抗特征一致。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照3期试验,在20个国家75个中心招募受试者。
  • 纳入病程≤60个月、筛查时mRSS为10-35的弥漫性皮肤型系统性硬化症成人。
  • 按1:1随机接受每周皮下托珠单抗162 mg或安慰剂,共48周,按IL-6水平分层。
  • 主要终点为基线至第48周mRSS变化值的组间差异。

主要发现

  • 意向治疗人群中,mRSS从基线至第48周最小二乘均值变化:托珠单抗-6·14,安慰剂-4·41,校正差值-1·73(95%CI -3·78至0·32;p=0·10)。
  • 第48周FVC%预测值变化分布倾向托珠单抗(van Elteren名义p=0·002 vs 安慰剂),最小二乘均值差4·2(95%CI 2·0-6·4;名义p=0·0002)。
  • 治疗失败时间:风险比0·63(95%CI 0·37-1·06;名义p=0·08)。
  • HAQ-DI及患者整体、医生整体视觉模拟量表评估的变化在两组间无差异。
  • 安全性集中感染最常见:托珠单抗组54/104(52%),安慰剂组53/106(50%)。

关键数值与推荐

  • 主要终点mRSS变化组间校正差值-1·73(95%CI -3·78至0·32;p=0·10),未达统计学意义。
  • FVC%预测值变化最小二乘均值差4·2(95%CI 2·0-6·4;名义p=0·0002),分布比较van Elteren名义p=0·002。
  • 治疗失败时间风险比0·63(95%CI 0·37-1·06;名义p=0·08)。
  • 严重不良事件:托珠单抗组13例,安慰剂组18例,主要为感染(3例 vs 8例)和心脏事件(2例 vs 7例)。

临床怎么用

  • 对早期弥漫性皮肤型系统性硬化症合并SSc-ILD且急性期反应物升高者,可考虑托珠单抗以潜在延缓肺功能下降。
  • 皮肤纤维化方面不应期待托珠单抗带来显著mRSS改善,主要终点未达到。
  • 用药期间需关注感染及心脏事件等不良事件,安全性与此前已知特征一致。

局限性

  • 主要终点未达到,FVC%预测值等次要终点结果为名义p值,需谨慎解读。
  • 研究仅纳入病程≤60个月、mRSS 10-35的弥漫性皮肤型系统性硬化症患者,外推受限。
  • 原文摘要未报告样本量以外的其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor antibody, in the treatment of systemic sclerosis. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, participants were recruited from 75 sites in 20 countries across Europe, North America, Latin America, and Japan. Adults with diffuse cutaneous systemic sclerosis for 60 months or less and a modified Rodnan skin score (mRSS) of 10-35 at screening were randomly assigned (1:1) with a voice-web-response system to receive subcutaneous tocilizumab 162 mg or placebo weekly for 48 weeks, stratified by IL-6 levels; participants and investigators were masked to treatment group. The primary endpoint was the difference in change from baseline to week 48 in mRSS. Percentage of predicted forced vital capacity (FVC% predicted) at week 48, time to treatment failure, and patient-reported and physician-reported outcomes were secondary endpoints. This trial is registered with ClinicalTrials.gov (number NCT02453256) and is closed to accrual. FINDINGS: Between Nov 20, 2015, and Feb 14, 2017, 210 individuals were randomly assigned to receive tocilizumab (n=104) or placebo (n=106). In the intention-to-treat population, least squares mean [LSM] change from baseline to week 48 in mRSS was -6·14 for tocilizumab and -4·41 for placebo (adjusted difference -1·73 [95% CI -3·78 to 0·32]; p=0·10). The shift in distribution of change from baseline in FVC% predicted at week 48 favoured tocilizumab (van Elteren nominal p=0·002 vs placebo), with a difference in LSM of 4·2 (95% CI 2·0-6·4; nominal p=0·0002), as did time to treatment failure (hazard ratio 0·63 [95% CI 0·37-1·06]; nominal p=0·08). Change in LSM from baseline to week 48 in Health Assessment Questionnaire-Disability Index and in patient-global and physician-global visual analogue scale assessments did not differ between tocilizumab and placebo. In the safety set, infections were the most common adverse events (54 [52%] of 104 participants in the tocilizumab group, 53 [50%] of 106 in the placebo group). Serious adverse events were reported in 13 participants treated with tocilizumab and 18 with placebo, primarily infections (three events, eight events) and cardiac events (two events, seven events). INTERPRETATION: The primary skin fibrosis endpoint was not met. Findings for the secondary endpoint of FVC% predicted indicate that tocilizumab might preserve lung function in people with early SSc-ILD and elevated acute-phase reactants. Safety was consistent with the known profile of tocilizumab. FUNDING: F Hoffmann-La Roche Ltd.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020. PMID: 32866440. doi:10.1016/S2213-2600(20)30318-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。